Context:
First or early second trimester pregnancy-associated plasma protein-A (PAPP-A) concentrations have previously been shown to be lower in women who subsequently develop gestational diabetes (GDM) and gestational hypertension. Objective: We therefore sought to investigate why circulating PAPP-A concentrations are related to the subsequent risk of GDM and gestational hypertension.
Patients, Design and Setting:
We measured serum PAPP-A concentrations around week 15 of pregnancy and related these to indices derived from week 28 oral glucose tolerance tests (OGTT) and blood pressures across pregnancy in the Cambridge Baby Growth Study cohort.
Results:
Increased PAPP-A concentrations were associated with reduced GDM risk (odds ratio 0.623 (0.453, 0.856), P=3.5 x 10−3, n=777) and reduced mean arterial blood pressures (β=-0.202– -0.177, P=1.7–6.9 x 10−3, n=347–355). They were also negatively associated with week 28 fasting (β=-0.149, P=6.6 x 10−4, n=777) and 60 minute (β=-0.188, P=1.5 x 10-5, n=777) OGTT glucose concentrations. These associations were underpinned by the strong associations between increased week 15 PAPP-A concentrations and decreased week 28 insulin resistance (HOMA IR: β=-0.319, P=1.7 x 10−13, n=768), and increased insulin secretion relative to insulin sensitivity (insulin disposition index: β=0.202, P=6.5 x 10−6, n=731).
Conclusions:
These results suggest that links between PAPP-A concentrations in early pregnancy and subsequent glucose concentrations and blood pressures may be mediated by changes in insulin sensitivity (and secretion).Most of the endocrine measurements described in this study were funded by the Wellbeing of Women (the Royal College of Obstetricians and Gynaecologists, U.K.) (RG1644). Core funding for the Cambridge Baby Growth Study has come from the Medical Research Council (7500001180); European Union Framework 5 (QLK4-1999-01422); the Mothercare Charitable Foundation (RG54608); Newlife Foundation for Disabled Children (07/20) and the World Cancer Research Fund International (2004/03). In addition, there has been support from National Institute for Health Research Cambridge Biomedical Research Centre
